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The clinical, personal, and societal impact imposed by 
rheumatoid arthritis (RA) has transformed in the last decade. The 
likelihood of a more favorable disease course is increasing, being 
associated, more recently, with less articular damage and an 
improved long-term prognosis (1,2). This has been driven largely 
by a substantially revised treatment paradigm, comprising earlier 
diagnosis, treatment, and application of treat-to-target strategies, 
together with the advent of selective immune-targeted therapeutic 
strategies based on pathogenesis-driven principles.
However, rates of remission of RA remain low, especially 
“drug-free” remission (2). In a large RA study, remission rates 
ranged between 8.6% and 19.6%, depending on the medical 
center where data were obtained and the definition of remission 
used (3). Some individuals remain partial responders whereas 
a significant minority of patients are truly “difficult to treat.” An 
important consequence of the unmet needs of these “difficult- 
to-treat” RA patients is irreversible damage and a substantial 
residual loss of quality of life. Difficult-to-treat RA poses the great-
est challenges to rheumatologists and also has a wider societal 
impact driven by various factors, including higher health care utili-
zation, social isolation, and work disability.
Rheumatoid arthritis is not simply a disease of the joints. It 
is a multifaceted, chronic, systemic disorder that is characterized 
by additional classic extraarticular RA-related features such as 
interstitial lung disease (ILD). Uncontrolled inflammation can also 
result in notable comorbidities of disease, such as osteoporosis, 
increased cardiovascular risk, recurrent infections, and substantial 
cognitive dysfunction (4). Moreover, some of these conditions may 
be the consequence of treatments, such as glucocorticoids. 
Thus, the disease impact in patients with RA may be limited to 
articular manifestations only (a less likely scenario) but could 
also involve extraarticular manifestations, such as complications 
due to therapies, or comorbidities. The latter scenarios are more 
representative of “real-life” conditions and pose additional chal-
lenges for complex disease management strategies designed to 
optimize outcomes. The poorer prognosis associated with these 
complex scenarios in RA, especially multimorbidity, necessitates 
a revision of the current treatment strategy that should stimulate 
the research agenda.
What is irreversible damage in RA?
Irreversible damage in RA, whether of the joints or of other 
organs, necessitates attention, both in routine clinical practice 
and in clinical research. Conventionally, the phrase “irreversible 
damage in RA” is used in the context of articular damage that 
can subsequently lead to deformity, loss of function, and chronic 
pain. Although orthopedic surgery has been studied as a surro-
gate marker of end-stage joint destruction (5), radiographic dam-
age using validated scores, such as the Larsen or Sharp/van 
der Heijde scores, are now the standard in assessing this type 
of damage (6,7). Though widely used in academic context and 
in trials, the use of these validated scores in everyday practice is 
limited, and it is self-evident that they quantify only a small compo-
nent of the damage burden placed on the patient.
The damage seen in RA reflects chronic inflammation, 
immune-mediated tissue injury, and accelerated comorbidity; 
it may also be iatrogenic. Potentially any organ/tissue can be 
affected and may result in multisystem disease, with both physical 
and psychological manifestations, as described above. Should we 
now consider the development of usable indices that more widely 
reflect the damage accrual in patients with RA—such as an index 
that would include parameters not only in the joints, but also in 
other tissues? To answer this question, one needs to consider the 
value of such an index, especially in routine clinical practice. Pre-
vious attempts to design clinical damage scores did not receive 
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wide adoption despite being associated with disease activity and 
other disease-related indices. The Overall Status in Rheumatoid 
Arthritis (OSRA) is an example. OSRA is a simple measure of over-
all status that consists of 4 components, with 1 being a disease 
damage score (8). The Rheumatoid Arthritis Articular Damage 
(RAAD) score is another example, developed as a clinical method 
for scoring long-term articular damage in patients with RA (9). Of 
note, none of these scores have been developed to capture per-
manent global damage in RA. Moreover, they were published in 
an era when multimorbidity in RA was underrecognized, which is 
perhaps why, at least in part, their wider acceptability and imple-
mentation was hindered.
What have we learned from other diseases?
There are 2 important concepts to consider when we 
attempt to define damage: chronicity and reversibility. For many 
immune-mediated inflammatory diseases, such as systemic 
lupus erythematosus, Sjögren’s syndrome, and vasculitis, disease 
damage indices have been developed in order to measure irre-
versible organ damage and to better describe treatment efficacy 
and disease prognosis (10–12). These tools have been important 
for measuring permanent injury and have been used in clinical 
studies as well as translational research studies. These indices 
use the concept of irreversible damage, as distinct from active 
and reversible inflammatory processes which would be expected 
to respond to immunosuppression. In some of these indices, the 
duration of signs/symptoms aids in the distinction between per-
manent and temporary damage (10,11). These indices have found 
a place in the routine management and monitoring of their respec-
tive diseases. Beyond their clinical value, they are also widely used 
for research purposes, such as in the study of treatment strategies 
and disease progression and characteristics, as well as mortality 
and other potentially preventable adverse outcomes like functional 
disability and drug-related side effects (13). However, significant 
limitations have been identified regarding the content of these 
indices and their implementation in everyday clinical practice (14).
Envisioning a global damage index in RA
Thus far, a global damage index comprising all possible 
causes of permanent damage, such as articular, extraarticu-
lar, comorbid systemic involvement, and iatrogenic damage, 
does not exist. We envision a damage index that consists of the 
 following domains: 1) articular and extraarticular manifestations, 
2) comorbidities, and 3) iatrogenic damage (Figure 1). Each domain 
in turn will be characterized by relevant aspects of the “fields” of dis-
ease related to that domain. These characteristics could include, 
for example, neurologic manifestations, ILD,  and radiograph ic 
damage for articular and extraarticular manifestations; cardiovas-
cular disease and mental health disorders for comorbidities; and 
demyelination for iatrogenic damage. Fields may be scored in a 
weighted manner. The sum score of the fields of each domain 
can provide the domain score. The sum of the domain scores can 
provide a score for the damage index. To derive such a score, a 
working group comprising experts in the field from various 
relevant disciplines (rheumatologists, health care providers in 
rheumatology, epidemiologists, and statisticians) should be 
included in the development of this index. Patient participation 
in this project will be of paramount importance to obtain input via 
focus groups and face-to-face meetings and by online surveys 
 distributed by patients’ organizations.
Figure 1. Domains and fields proposed for a new rheumatoid arthritis damage index. Different layers represent the domains of the index, with 
examples provided for fields that can be included in each domain.
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A damage index would serve as a useful tool in clinical 
practice and in research, although the needs between these 
areas might differ. In terms of clinical practice, we seek holistic 
care in RA management. First, it appears that certain subgroups 
of RA patients are undertreated or overtreated using existing ther-
apeutic adjustment tools (for example, treat-to-target principles 
that do not include multimorbidity in treatment algorithms) (15). 
Concerning residual and irreversible damage, redefining our tar-
gets and treatment strategies in RA would be helpful in improving 
outcomes. Second, such an index could help define a subgroup 
of patients in whom damage is more readily accumulated. These 
individuals could be either patients who have irreversible damage 
(i.e., erosions or ILD) at the time of symptom onset/disease diag-
nosis or patients who, during their disease course, quickly accu-
mulate significant damage. Regardless, patients who continue 
to accrue damage despite achievement of effective control of 
inflammation (as determined by clinical and laboratory measures) 
would be promptly recognized with this proposed damage index. 
Third, mortality is still increased in RA mainly due to comorbidi-
ties and extraarticular manifestations. These disease features are 
at least partly preventable, and therefore, it is vital to understand 
what drives irreversible damage in RA. A novel global damage 
index in RA may have value in this respect.
In addition to the above points, an RA damage index could be 
very useful for clinical research in RA. It could be utilized to  compare 
different interventions in preventing damage, enabling compari-
sons to be made between patients with similar disease burden 
(i.e., comorbidities, extraarticular manifestations, and drug-related 
damage). Besides, a known problem is that there are discrepan-
cies between results demonstrated in randomized controlled trials 
(RCTs) and data obtained from real-world medical practice. This 
is partly because of the strict inclusion/exclusion criteria of RCTs, 
which tend to exclude patients with significant comorbidities 
and/or extraarticular manifestations and complications.
Such an index is expected to have high clinical and research 
impact. Accordingly, several aspects need to be considered. One 
would have to think carefully about the sensitivity of the analyses in 
terms of the criteria for risk stratification of the patients and weigh-
ing of the data. One should also acknowledge that construction of 
such an index would necessitate a careful and stepwise approach 
to ensure its value, such as, for example, in preventing further 
damage in a patient once the patient is identified as having irre-
versible damage, and especially in the preservation of function 
and quality of life in these patients. The need for a minimum sever-
ity grade for a feature to be included in such an index or the need 
for a range of severity grades and different scoring would have 
to be discussed. Additionally, direct and obvious relation to RA 
should be taken into consideration, with the caveat that certain 
comorbidities might be unrelated to RA. The sensitivity of such 
an index to identify those individuals who might benefit from more 
aggressive preventative treatment or those individuals who are 
overtreated would also need to be considered.
Conclusions
Although joint damage is the prominent feature of damage 
accrual in RA, it is certainly not the only one. The avail able joint 
damage scores have high academic value but are not widely 
used in clinical settings. Several organs can be irreversibly 
damaged in RA due to autoimmune mechanisms and chronic 
inflammation, comorbid acceleration, and drug toxicity. A clini-
cal index that involves different domains apart from joint dam-
age is needed as a more realistic reflection of the global impact 
of disease on patients we treat in real-world settings. Such an 
index should have high clinical value, enabling rheumatologists 
to “summarize” damage and stratify patients according to the 
severity of the global damage, identify more aggressive disease, 
and predict progression and poor outcomes in terms of both 
higher morbidity and mortality. A global damage index for RA 
could guide more individualistic disease management, improve 
treatment decisions, and lead to more patient-centric and holis-
tic care.
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Clinical Images: Cerebral vertebral artery vasculitis presenting as neck pain and fever
DOI 10.1002/art.41448
The patient, a 64-year-old man, was admitted to our hospital with a 6-week history of intermittent neck pain, posterior headaches, fever 
(39°C), and inflammatory syndrome (persistently elevated C-reactive protein level [~200 mg/liter]). Because of a dry cough, bronchopneu-
monia was initially suspected; however, antibiotics were not effective. He had not experienced vision loss or jaw or limb claudication and was 
not experiencing any headache at the time of admission. He had been diagnosed as having polymyalgia rheumatica (PMR) 3 years prior, 
which was still being treated with methotrexate. Because of the immunosuppressive drugs, we initially suspected infectious spondylodiscitis, 
but magnetic resonance imaging (MRI) of the neck showed only cervical arthrosis. Blood cultures were sterile. 18F-labeled fluorodeoxyglucose 
positron emission tomography with computed tomography (18F-FDG-PET/CT)–derived maximum intensity projection (A) showed pathologic 
uptake in the vertebral, supraclavicular, and mammary arteries and the aortic wall (fused axial PET/CT [B], coronal PET/CT [C], and sagittal 
PET/CT [D]). Large vessel vasculitis (LV V) consistent with giant cell arteritis (GCA) was diagnosed. Previous treatment was discontinued, and 
treatment with prednisone and tocilizumab (anti–interleukin-6 receptor monoclonal antibody) was initiated, greatly improving neck pain and 
inflammatory syndrome. Posterior headaches can be symptomatic of LV V-like GCA or Takayasu arteritis. Inflammation of vertebral arteries 
and structural damage are more specifically observed in GCA (1). GCA should be suspected in patients >50 years old with unusual head-
aches, associated PMR, and prolonged inflammatory syndrome. Temporal artery biopsy must be performed to confirm the diagnosis, even 
though the sensitivity of the histologic signs is only ~77% (2). In the Giant Cell Arteritis Clinical Research Study, new criteria were proposed, 
including morphologic signs of vasculitis, such as thickening of the aortic wall (on CT or MRI) or pathologic 18F-FDG uptake in large vessels 
(on 18F-FDG-PET/CT). In the case of a negative temporal artery biopsy finding, pathologic 18F-FDG uptake in the vertebral arteries seems to 
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